The effects of intranasal oxytocin on the efficacy of psychotherapy for major depressive disorder: a pilot randomized controlled trial
Mark A Ellenbogen,Christopher Cardoso,Lisa Serravalle,Kiran Vadaga,Ridha Joober,Mark A. Ellenbogen
DOI: https://doi.org/10.1017/s0033291724000217
IF: 10.592
2024-03-07
Psychological Medicine
Abstract:Background Although both pharmacotherapy and psychological treatments are considered to be efficacious in the treatment of major depressive disorder (MDD), one third of patients do not respond to treatment and many experience residual symptoms post-treatment. In this double-blind placebo-controlled randomized control trial (RCT), we assessed whether intranasal oxytocin (OT) augments the therapeutic efficacy of psychotherapy for MDD and improves the therapeutic alliance. Methods Twenty-three volunteers (12 female) with MDD underwent 16 sessions of interpersonal therapy. Prior to each session, volunteers self-administered 24 International Units of intranasal OT (n = 12; Syntocinon) or placebo (n = 11). Depressive symptoms were assessed with the Inventory of Depressive Symptomatology at pre- and post-treatment, and at a six month follow-up. Results Multilevel modeling found a significant effect of OT on the negative slope of depressive symptoms over time (p < 0.05), with medium-large effect sizes at post-treatment (Cohen's d = 0.75) and follow-up (Cohen's d = 0.82). Drug intervention also predicted the intercept when examining the weekly ratings of the therapeutic alliance (p < 0.05), such that volunteers receiving OT, relative to placebo, reported improved therapeutic alliance at session 1. The agreement of goals between therapists and participants, a facet of the therapeutic alliance, mediated the relationship between drug intervention and clinical outcome. Conclusion In this pilot study, the administration of intranasal OT, relative to placebo, improved the therapeutic alliance at the beginning of therapy and therapeutic efficacy of psychotherapy in persons with MDD. Future RCTs should attempt to replicate these findings in larger samples with different therapeutic modalities (ClinicalTrials.gov: NCT02405715).
psychiatry,psychology, clinical
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to evaluate whether intranasal oxytocin (OT) can enhance the efficacy of psychotherapy for patients with major depressive disorder (MDD) and improve the therapeutic alliance. Specifically, the researchers hope to explore the following points through a double - blind placebo - controlled randomized controlled trial (RCT):
1. **Treatment effect**: Whether intranasal oxytocin can significantly reduce the depression symptom scores of MDD patients after treatment and at the six - month follow - up compared with placebo.
2. **Therapeutic alliance**: Whether intranasal oxytocin can improve the therapeutic alliance between patients and therapists, especially the effect at the beginning of treatment.
3. **Mediating effect**: Whether the change in the therapeutic alliance can mediate the relationship between drug intervention and clinical effect.
### Research background
Although both drug treatment and psychotherapy are considered effective for MDD in the short term, about one - third of patients do not respond to treatment, and many still have residual symptoms after treatment. In addition, about 40 - 50% of patients drop out early or fail to achieve complete clinical remission after acute - phase treatment. Among the patients who are successfully treated, about 30% and 55% relapse within one year and two years respectively. Therefore, more effective treatment strategies are needed to improve the treatment effect of MDD.
### Research methods
The study recruited 23 MDD patients and randomly divided them into two groups. One group received interpersonal psychotherapy (IPT) combined with intranasal oxytocin (OT), and the other group received IPT combined with placebo. Participants self - administered 24 international units of oxytocin or placebo intranasally 30 minutes before each treatment. The study evaluated depressive symptoms through the Inventory of Depressive Symptomatology (IDS - C) and evaluated the therapeutic alliance through the Working Alliance Inventory - Short Form (WAI - S).
### Main findings
1. **Changes in depressive symptoms**:
- Multilevel modeling analysis showed that the slope of the decrease in the depression symptom scores in the oxytocin group over time was significant (p < 0.05), and the effect sizes at post - treatment and follow - up were medium to large respectively (Cohen's d = 0.75 and 0.82).
- The response rate of achieving 50% symptom reduction in the oxytocin group after treatment was significantly higher than that in the placebo group (χ²[1, N = 23]= 4.1, p = 0.043), but there was no significant difference at the follow - up, which may be due to the ceiling effect already reached after treatment.
2. **Changes in the therapeutic alliance**:
- The oxytocin group reported significantly higher therapeutic alliance scores at the beginning of treatment (after the first session) than the placebo group (p < 0.05).
- Over time, the therapeutic alliance scores in the placebo group gradually increased and finally became comparable to those in the oxytocin group.
3. **Mediating effect**:
- The change in the therapeutic alliance partially mediated the relationship between drug intervention and clinical effect, especially in terms of the consistency of treatment goals.
### Conclusion
This study preliminarily shows that intranasal oxytocin can improve the therapeutic alliance in MDD patients and enhance the efficacy of psychotherapy. Future research needs to verify these findings in larger samples and different treatment models.